Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5141]

SMMART Program: A multi-omics tumour board with a focus on breast cancer

Dr Ben Kong - Oregon Health & Science University, Portland, USA

SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )

Clinical validation of a targeted methylation-based multi-cancer early...

Dr Eric Klein - Cleveland Clinic, Cleveland, USA

Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than...

Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )

High-quality neoantigens are immunoedited in long-term survivors of pancreatic...

Prof Marta Luksza - Tisch Cancer Institute, New York, USA

High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer ( Prof Marta Luksza - Tisch Cancer Institute, New York, USA )

First-line pembrolizumab plus chemotherapy for patients with advanced squamous...

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General...

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Highlights from AORTIC Cancer Genomics Conference 2021

Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center...

Highlights from AORTIC Cancer Genomics Conference 2021 ( Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, Accra, Ghana )

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Prof Ales Ryska - Charles University, Prague, Czech Republic

Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC...

Prof Andrea Filippi - University of Pavia, Pavia, Italy

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy ( Prof Andrea Filippi - University of Pavia, Pavia, Italy )

Cancer Genomics in Africa today

Dr Solomon Rotimi - Covenant University, Ota, Nigeria

Cancer Genomics in Africa today ( Dr Solomon Rotimi - Covenant University, Ota, Nigeria )

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for March 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer